Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib mesylate (gleevec) hepatotoxicity.

× No keyword cloud information.

9 in total

1. Fatal hepatic necrosis following imatinib mesylate therapy.

Authors: Nancy U Lin; Stefanie Sarantopoulos; James R Stone; Ilene Galinsky; Richard M Stone; Daniel J Deangelo; Robert J Soiffer
Journal: Blood Date: 2003-11-01 Impact factor: 22.113

2. Histological features of acute hepatitis after imatinib mesylate treatment.

Authors: C James; H Trouette; G Marit; P Cony-Makhoul; F-X Mahon
Journal: Leukemia Date: 2003-05 Impact factor: 11.528

3. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.

Authors: K Ohyashiki; Y Kuriyama; A Nakajima; T Tauchi; Y Ito; H Miyazawa; Y Kimura; H Serizawa; Y Ebihara
Journal: Leukemia Date: 2002-10 Impact factor: 11.528

4. Imatinib (Gleevec)-induced hepatotoxicity.

Authors: Walid S Ayoub; Stephen A Geller; Tram Tran; Paul Martin; John M Vierling; F Fred Poordad
Journal: J Clin Gastroenterol Date: 2005-01 Impact factor: 3.062

5. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Authors: Martin H Cohen; Grant Williams; John R Johnson; John Duan; Jogarao Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann M Staten; Richard Pazdur
Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531

6. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes.

Authors: Satoru Kikuchi; Kazuo Muroi; Satoko Takahashi; Chizuru Kawano-Yamamoto; Masaaki Takatoku; Akira Miyazato; Tadashi Nagai; Masaki Mori; Norio Komatsu; Keiya Ozawa
Journal: Leuk Lymphoma Date: 2004-11

7. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors: B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245

8. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Authors: John R Johnson; Peter Bross; Martin Cohen; Mark Rothmann; Gang Chen; Anne Zajicek; Joga Gobburu; Atiqur Rahman; Ann Staten; Richard Pazdur
Journal: Clin Cancer Res Date: 2003-06 Impact factor: 12.531

Review 9. Indications for imatinib mesylate therapy and clinical management.

Authors: François Guilhot
Journal: Oncologist Date: 2004

9 in total

4 in total

1. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors.

Authors: Onder Tonyali; Ugur Coskun; Ramazan Yildiz; Tarkan Karakan; Umut Demirci; Nalan Akyurek; Mustafa Benekli; Suleyman Buyukberber
Journal: Med Oncol Date: 2009-08-07 Impact factor: 3.064

2. Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.

Authors: Mohamed E Shaker; Khaled R Zalata; Wajahat Z Mehal; Gamal E Shiha; Tarek M Ibrahim
Journal: Toxicol Appl Pharmacol Date: 2011-02-24 Impact factor: 4.219

Review 3. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors: Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal: Expert Rev Anticancer Ther Date: 2013-12 Impact factor: 4.512

4. Factors Influencing Imatinib-Induced Hepatotoxicity.

Authors: Ji Min Han; Jeong Yee; Yoon Sook Cho; Hye Sun Gwak
Journal: Cancer Res Treat Date: 2019-06-26 Impact factor: 4.679

4 in total